Priority Healthcare Distribution DB Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Priority Healthcare Distribution DB Pharmaceutical Import Records from India — 2 Products, $700.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Priority Healthcare Distribution DB — Pharmaceutical Importer Profile (2026) | 2 Products, $700.0K Trade | TransData Nexus

Priority Healthcare Distribution DB

Pharmaceutical Importer · United States · Antimalarial & Antiparasitic Focus · $700.0K Total Trade · DGFT Verified

Priority Healthcare Distribution DB is a pharmaceutical importer based in United States with a total trade value of $700.0K across 2 products in 1 therapeutic categories. Based on 14 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Priority Healthcare Distribution DB sources from 13 verified Indian suppliers, with Zydus Lifesciences Limited accounting for 38.6% of imports.

Priority Healthcare Distribution DB — Import Portfolio & Supplier Network

Priority Healthcare Distribution DB import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Priority Healthcare Distribution DB?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Zydus Lifesciences Limited	$5.3M	117	38.6%
Cipla Limited	$3.3M	174	24.0%
Cadila Healthcare Limited

What Formulations Does Priority Healthcare Distribution DB Import?

Formulation	Value	Ships
Pharmaceutical medicine for human use-	$1.6M	34
Pharmaceutical medicine for human use-	$689.5K	14
Pharmaceutical medicine for human use-	$535.4K	11
Pharmaceutical medicine for human use-	$300.0K	6
Pharmaceutical medicine for human use- hydroxychloroquine sulfate tablets USP 200 MG - 1 x	$300.0K	6
Pharmaceutical medicine for human use- tamsulosin hcl cap USP 0.4 MG - 1 x	$300.0K	6
Pharmaceutical medicine for human use- tamsulosin hcl cap USP 0.4 MG - 1 x	$250.0K	5
300038464 omeprazoledrcapstusp20mg1000sq	$223.7K	9
Amlodipine besylate tablets USP 10 MG (inv.qty.3888 Pack 1x1000s=3888000 nos)	$182.5K	5
Amlodipine besylate tablets USP 10MG	$180.8K	5
Esomeprazole magnesium delayed-release	$159.6K	4
Pharmaceutical medicine for human use- losartan potassium tablet USP 25 MG - 1	$151.3K	6
Pharmaceutical medicine for human	$150.0K	3
Bupropion hcl er TAB USP 300MG 500s qualbupropion hydrochloride extended release tablets USP	$150.0K	3
Bupropion hcl er TAB USP 150MG 500s qualbupropion hydrochloride extended release tablets USP	$150.0K	3

Priority Healthcare Distribution DB imports 248 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Chloroquine	Antimalarial & Antiparasitic	$350.0K	7	0.2%	11
2	Hydroxychloroquine	Antimalarial & Antiparasitic	$350.0K	7	0.2%	8

Priority Healthcare Distribution DB imports 2 pharmaceutical products across 1 categories into United States totaling $700.0K.

Priority Healthcare Distribution DB — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Priority Healthcare Distribution DB, operating under the trade name Curascript SD Specialty Distribution, is a prominent pharmaceutical distributor based in Lake Mary, Florida. Established in 1992, the company specializes in providing integrated delivery solutions for specialty pharmaceuticals and medical supplies to a diverse range of medical providers, including federal agencies. In October 2005, Priority Healthcare was acquired by Express Scripts Holding Co., a leading pharmacy benefit management organization, enhancing its capabilities in specialty pharmaceutical distribution.

As a key player in the United States pharmaceutical supply chain, Priority Healthcare Distribution DB serves as a primary wholesaler and specialty distributor. The company is registered with the U.S. federal government under the Unique Entity Identifier (UEI) JCVFNPM8CNS3 and holds a CAGE Code of 3CCQ4, reflecting its active participation in federal contracting. Its extensive experience and strategic partnerships position it as a significant entity in the distribution of specialty pharmaceuticals across the nation.

2Distribution Network

Priority Healthcare Distribution DB operates a comprehensive distribution network with multiple warehouse locations across the United States. Notably, the company has facilities in Grove City, Ohio, and Memphis, Tennessee, facilitating efficient logistics and timely delivery of pharmaceutical products. The company's logistics capabilities are further demonstrated by its import activities, with shipments arriving at major U.S. ports such as Savannah, Georgia, and Norfolk, Virginia. This extensive network ensures broad geographic coverage, enabling Priority Healthcare Distribution DB to meet the diverse needs of its clientele across the country.

3Industry Role

In the United States pharmaceutical supply chain, Priority Healthcare Distribution DB functions primarily as a wholesaler and specialty distributor. The company plays a crucial role in sourcing, importing, and distributing a wide array of pharmaceutical products, including specialty medications, to various healthcare providers. Its operations encompass the procurement of pharmaceutical products from international suppliers, such as Indian manufacturers, and their subsequent distribution to healthcare facilities, pharmacies, and government agencies. This position underscores the company's integral role in ensuring the availability and accessibility of essential medications within the U.S. healthcare system.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Priority Healthcare Distribution DB

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Priority Healthcare Distribution DB's sourcing strategy exhibits a significant concentration on a limited number of products, with a portfolio comprising only two products—Chloroquine and Hydroxychloroquine—both within the Antimalarial & Antiparasitic therapeutic category. This focus results in a portfolio concentration where the top five products account for 100% of the company's imports. Such a concentrated sourcing approach may present risks, including vulnerability to supply chain disruptions affecting these specific products. However, this strategy could also be a deliberate choice to specialize in high-demand, niche therapeutic areas, potentially allowing for optimized procurement and distribution processes. The stability of the company's supplier relationships is evidenced by its engagement with multiple Indian pharmaceutical manufacturers, indicating a diversified supplier base that may mitigate some risks associated with sourcing concentration.

2Supply Chain Resilience

The resilience of Priority Healthcare Distribution DB's supply chain is bolstered by its diversified supplier base, comprising 13 unique Indian pharmaceutical manufacturers. This diversity enhances the company's ability to adapt to potential disruptions, such as production delays or regulatory changes affecting individual suppliers. The company's focus on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, sourced from India, suggests a strategic emphasis on leveraging India's robust pharmaceutical manufacturing capabilities. While the concentration on a single therapeutic category may limit the breadth of the product portfolio, the company's established relationships with multiple suppliers within this category provide a degree of flexibility and security in its supply chain operations.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation, approval, and distribution of pharmaceutical products. The FDA enforces regulations that ensure the safety, efficacy, and quality of drugs entering the U.S. market. Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act, which provides the legal framework for drug approval and regulation. The FDA's Center for Drug Evaluation and Research (CDER) is responsible for evaluating new drugs and monitoring the safety of existing drugs. For Indian generics to be marketed in the U.S., they must undergo the FDA's Abbreviated New Drug Application (ANDA) process, demonstrating bioequivalence to the reference listed drug. This pathway ensures that generic drugs meet the FDA's standards for safety, efficacy, and quality before they are approved for sale in the U.S.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the United States are stringent. All imported drugs must be approved by the FDA, and the manufacturing facilities must comply with Good Manufacturing Practice (GMP) standards. The FDA recognizes GMP certifications from various international bodies, including the European Union (EU) GMP, World Health Organization (WHO) GMP, and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). These certifications indicate that the manufacturing processes meet internationally recognized quality standards. Additionally, wholesale distribution authorization is required for entities involved in the distribution of pharmaceutical products within the U.S. This authorization ensures that distributors adhere to regulatory requirements and maintain the integrity of the pharmaceutical supply chain.

Priority Healthcare Distribution DB — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Priority Healthcare Distribution DB's focus on importing antimalarial and antiparasitic medications, specifically Chloroquine and Hydroxychloroquine, aligns with the company's strategic emphasis on specialty pharmaceuticals. The market demand for these products is driven by their critical role in the treatment and prevention of malaria and other parasitic infections, particularly in regions with high prevalence rates. By specializing in this therapeutic area, Priority Healthcare Distribution DB can leverage its expertise to manage the complexities associated with the distribution of these specialized medications, including regulatory compliance, storage requirements, and distribution logistics.

2Sourcing Profile

Priority Healthcare Distribution DB's sourcing strategy is centered on generic drugs, with a particular emphasis on formulations such as tablets and injections. India's well-established pharmaceutical manufacturing industry, known for its adherence to international quality standards and cost-effective production capabilities, makes it an attractive sourcing destination. By importing finished pharmaceutical formulations from India, Priority Healthcare Distribution DB can offer a reliable supply of high-quality medications to meet the needs of its U.S. clientele.

3Market Positioning

Seller's Guide — How to Become a Supplier to Priority Healthcare Distribution DB

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to partner with Priority Healthcare Distribution DB, particularly those specializing in antimalarial and antiparasitic medications. The company's established distribution network and focus on specialty pharmaceuticals create a conducive environment for collaboration. Indian exporters can explore this opportunity by ensuring their products meet FDA standards, obtaining necessary certifications, and aligning with the therapeutic focus of Priority Healthcare Distribution DB. By addressing these requirements, Indian suppliers can position themselves as valuable partners in the U.S. pharmaceutical market.

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Priority Healthcare Distribution DB

What products does Priority Healthcare Distribution DB import from India?

Priority Healthcare Distribution DB imports 2 pharmaceutical products across 1 categories. Top imports: Chloroquine ($350.0K), Hydroxychloroquine ($350.0K).

Who supplies pharmaceuticals to Priority Healthcare Distribution DB from India?

Priority Healthcare Distribution DB sources from 13 verified Indian suppliers. The primary supplier is Zydus Lifesciences Limited (38.6% of imports, $5.3M).

What is Priority Healthcare Distribution DB's total pharmaceutical import value?

Priority Healthcare Distribution DB's total pharmaceutical import value from India is $700.0K, based on 14 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Priority Healthcare Distribution DB focus on?

Priority Healthcare Distribution DB imports across 1 categories. The largest: Antimalarial & Antiparasitic (100.0%).

Get Full Priority Healthcare Distribution DB Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.